1.
Women.
2.
Non-Caucasian.
3.
Excessive obesity defined as Body Mass Index (BMI) above 35 kg/m 2 , rounded to the nearest whole number.
4. LDL-C > 190 mg/dL at screening.
5.
Fasting triglycerides > 400 mg/dL at screening.
6.
Diabetes mellitus, defined as a fasting glucose > 7 mmol/L, or taking diabetic therapy at screening.
7.
History of symptomatic cardiovascular disease including angina pectoris, acute myocardial infarction, or peripheral arterial disease including intermittent claudication.
8.
History of symptomatic cerebrovascular disease, including cerebrovascular haemorrhage, transient ischemic attack, or carotid endarterectomy.
9.
A current smoker or have smoked in the preceding 12 months 10. Consume more than 10 g of alcohol (equivalent to one 100 mL glass of table wine) per day 11. Have received statins, fibric acid derivatives, bile acid sequestrants, cholesterol absorption inhibitors (including ezetimibe) or nicotinic acid >500 mg per day in the previous year.
12. Have uncontrolled hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg). Patients may have their hypertension controlled with a calcium channel blocker, but must not receive treatment with a diuretic, beta-blocker, angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB). If the patient has previously received treatment with these therapies, they must have been discontinued at least 2 months previously.
3 13. Any conditions that cause secondary dyslipidaemia or increase the risk of statin therapy including alcoholism, autoimmune disease, nephrotic syndrome, uremia, any viral hepatitis clinically active within 12 months before study entry, obstructive hepatic or biliary disease, dysglobulinaemia or macroglobulinaemia, multiple myeloma, glycogen storage disease, porphyria, and uncontrolled hypothyroidism or hyperthyroidism. Controlled thyroid disease (normal serum thyroid stimulating hormone (TSH) and stable therapy for at least 3 months) is permitted.
14. History of pancreatic injury or pancreatitis, or impaired pancreatic function/injury as indicated by abnormal lipase.
15. Liver injury as indicated by serum transaminase levels (alanine aminotransferase/serum glutamic pyruvic transaminase [ALAT/SGPT], aspartate aminotransaminase/serum glutamic oxaloacetic transaminase [ASAT/SGOT]) >3 x upper limit of the reference range (ULRR).
16. Impaired renal function as indicated by serum creatinine levels >1.5 x ULRR at screening or eGFR by Cockroft formula less than 60 mL/min.
17. History of any muscle disease or unexplained elevation (>3 x ULRR) of serum creatine kinase (CK). 
